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Abstract
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression
of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique
molecular profile, aggressive behavior, distinct patterns of metastasis, and lack of targeted therapies.
Although not synonymous, the majority of triple-negative breast cancers carry the “basal-like”
molecular profile on gene expression arrays. The majority of BRCA1-associated breast cancers are
triple-negative and basal-like; the extent to which the BRCA1 pathway contributes to the behavior
of sporadic basal-like breast cancers is an area of active research. Epidemiologic studies illustrate a
high prevalence of triple-negative breast cancers among younger women and those of African
descent. Increasing evidence suggests that the risk factor profile differs between this subtype and the
more common luminal subtypes. Although sensitive to chemotherapy, early relapse is common and
a predilection for visceral metastasis, including brain metastasis, is seen. Targeted agents, including
epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and poly
(ADP-ribose) polymerase (PARP) inhibitors, are currently in clinical trials and hold promise in the
treatment of this aggressive disease.
In 2008, it is estimated that over 1 million women worldwide will be diagnosed with breast
cancer, of which 172,695 will be classified as “triple-negative.”[1] The triple-negative
phenotype encompasses a breast tumor subtype that is clinically negative for expression of the
estrogen and progesterone receptors (ER and PR) and lacks overexpression of the HER2
protein, with unique prognostic and therapeutic implications.
Over the past decade, our understanding and treatment of breast cancer has undergone a
metamorphosis, shifting from a generally homogeneous approach to a more sophisticated view
as guided by gene expression analysis.[2] Multiple studies have reproducibly identified the
intrinsic breast cancer subtypes, which include several luminal subtypes characterized by
expression of hormone receptor–related genes, and two hormone receptor–negative subtypes
—the HER2-positive/ER-negative subtype and the “basal-like” subtype. Contrary to the
luminal subtypes, the basal-like subtype is characterized by low expression of ER- and HER2-
related genes and clinically is usually, but not always, ER/PR–negative and lack HER2 over-
expression, thereby constituting the “triple-negative” phenotype.
Multiple studies have demonstrated that the intrinsic subtypes vary by prognosis, with inferior
outcomes illustrated among the two hormone receptor–negative subgroups as compared to the
luminal subtypes.[3,4] They may also differ in other important ways. Recent studies suggest
that patients with triple-negative breast cancer have a high incidence of visceral metastasis,
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including brain metastasis. This clinically challenging scenario is an area of fertile research.
[5,6]
Unlike the other subtypes, targeted agents specifically aimed at triple-negative breast tumors
are not yet available, intensifying the need and interest in advancing novel therapeutic strategies
beyond chemotherapy for this subset of high-risk patients. This review will focus on the
molecular and clinicopathologic features, epidemiology and risk factors, prognosis, and current
and future therapeutic strategies for patients diagnosed with triple-negative breast cancer,
including a brief discussion of intracranial disease.
Definitions and Molecular Features
It is important to clarify the relationship between triple-negative breast cancer and the basal-
like phenotype. Triple-negative is a term based on clinical assays for ER, PR, and HER2,
whereas basal-like is a molecular phenotype initially defined using cDNA microarrays.[2,3]
Although most triple-negative breast tumors do cluster within the basal-like subgroup, these
terms are not synonymous; there is up to 30% discordance between the two groups.[7-10] In
this review we will use the term “basal-like” when microarray or more comprehensive
immunohistochemical profiling methodology was used, and “triple-negative” when the salient
studies relied on clinical assays for definition.
In order to fully understand the molecular and pathologic features classically associated with
the triple-negative phenotype, a review of the normal mammary gland parenchymal cells,
including their immunopheno-type, is essential. The more central luminal cells classically
express low-molecular-weight cytokeratins including CK7, CK8, CK18, and CK19, along with
MUC1 alpha-6 integrin, BCL1, ER, PR, and GATA3. Moving outward toward the basement
membrane, myoepithelial cells comprising the basal cell layer express high-molecular-weight
cytokeratins including CK5, CK14, and CK17 in addition to smooth muscle–specific markers,
calponin, caldesmon, p63, beta-4 integrin, laminin, maspin, CD10, P-cadherin, caveolin-1, and
nerve growth factor receptor (NGFR) and S100 (see Table 1).[11-16] Classically, basal-like
breast cancers have been characterized by low expression of ER, PR, and HER2 and high
expression of CK5, CK14, caveolin-1, CAIX, p63, and epidermal growth factor receptor
(EGFR, HER1), which reflects the mammary gland basal/ myoepithelial cell component.[1,
17]
Among this list of markers characteristic of triple-negative breast tumors, several are
potentially targetable, notably HER1/EGFR. A member of the “basal cluster” intrinsic gene
list, HER1/EGFR is expressed in approximately 60% of basal-like breast tumors.[10,18] It has
also been observed that c-Kit expression is higher in basal-like tumors. In one study, 31% of
tumors expressing basal cytokeratins had c-Kit staining compared to 11% in basal cytokeratin–
negative tumors (P < .001).[10]
Finally, several molecules integrally involved in DNA repair are aberrantly expressed in triple-
negative breast cancer, which may have implications for chemotherapy sensitivity. High p53
IHC expression or p53 gene mutations are common in basal-like breast cancer.[3,19]
Furthermore, one series illustrates that 82% of basal-like breast cancers expressed a p53
mutation compared with only 13% in the luminal A subtype (P < .001).[3] Several additional
and targetable molecular pathways implicated in the pathogenesis of basal-like breast cancer
include the mitogen-activated protein (MAP) kinase pathway, the Akt pathway, and the poly
ADP-ribose polymerase 1 (PARP1) pathway, which will be addressed in more detail in the
context of BRCA1 and therapeutics below.[8]
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Association With BRCA1 Mutation Status
It has been observed that the majority of BRCA1-associated breast cancers are triple-negative
and express a high proportion of basal-like cytokeratins (CK5, 14, 17), as well as P-cadherin
and HER1/EGFR.[20-24] The BRCA1 tumor-suppressor gene, originally identified in 1994
by positional cloning on chromosome 17q21, is a multifocal protein in many normal cellular
functions including DNA repair, transcriptional regulation, cell cycle checkpoint control, and
ubiquitination.[22,25]
Several studies have shown that breast tumors arising in women carrying germline mutations
of the BRCA1 tumor-suppressor gene are triple-negative.[24,26] Gene expression studies
support this association; among patients with BRCA1 mutations, breast tumors tend to cluster
within the basal-like category.[4] As BRCA1 is in part responsible for DNA repair, exploitation
of this essential pathway holds therapeutic implications in the context of the triple-negative
phenotype and will be discussed further below.
Clinical Characteristics, Epidemiology, and Risk Factors
Triple-negative breast tumors have been characterized by several aggressive clinicopathologic
features including onset at a younger age, higher mean tumor size, higher-grade tumors, and,
in some cases, a higher rate of node positivity.[27,28] A histologic study of basal-like tumors,
of which all were ER/HER2–negative, illustrated marked increases in mitotic count,
geographic necrosis, pushing borders of invasion, and stromal lymphocytic response.[29] The
majority of triple-negative breast carcinomas are ductal in origin; however, several other
aggressive phenotypes appear to be overrepresented, including meta-plastic, atypical or typical
medullary, and adenoid cystic.[8,27,30]
In parallel with our understanding of the molecular basis of triple-negative breast cancer, our
awareness of the epidemiology and risk factors associated with this disease process has
matured, specifically related to age and race. Among approximately 500 women evaluated in
the Carolina Breast Cancer Study, those with basal-like tumors (defined as ER-negative, PR-
negative, HER2-negative, CK 5/6-positive, and/or HER1-positive) were more likely to be
African-American (prevalence of 26% vs 16% in non–African-Americans) and premenopausal
(24% vs 15% postmenopausal). These investigators observed a particularly high prevalence
of basal-like tumors among premenopausal, African-American women compared to
postmenopausal African-American women and non–African-American women of any age
(39% vs 14% and 16%, respectively; P < .001).[27] These findings are consistent with several
large-scale, population-based studies indicating that triple-negative breast cancers are more
likely to occur among premenopausal women of African-American descent.[31,32]
Several epidemiologic studies have provided insight into risk factors associated with triple-
negative breast cancers. Further examination of approximately 1,400 breast cancer cases in the
Carolina Breast Cancer Study illustrated that compared to luminal A tumors (ER-positive and/
or PR-positive and HER2-negative), basal-like breast tumors were more likely to arise among
women with a younger age at menarche, higher parity, younger age at full-term pregnancy,
shorter duration of breast-feeding, and higher body mass index (BMI) and waist-tohip ratio
(WHR), especially among premenopausal patients. Additionally, those who used methods to
suppress lactation were also at higher risk for basal-like breast cancers compared to luminal A
breast cancers.[33] Although not definitive, these findings suggest that among younger
African-American women, close to two-thirds of aggressive, basal-like breast cancers might
be prevented by promoting breast-feeding and decreasing abdominal obesity.
Similarly, the Polish Breast Cancer Study demonstrated a stronger reduction in risk associated
with increasing age at menarche for basal-like tumors compared to luminal A–type breast
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cancer. Among premenopausal women, increasing BMI was associated with a reduced risk of
luminal but not basal-like breast cancers.[34] These findings illustrate that breast cancer risk
factors vary by molecular subtype (ie, luminal A, basal-like, etc), supporting subtype-specific
approaches when examining risk factors and prevention.
Prognosis
The inferior prognosis associated with triple-negative breast cancer was originally recognized
in the initial studies examining outcome by intrinsic subtype. These studies uniformly
demonstrated a poorer prognosis among patients with breast cancer classified as “basal-like,”
particularly compared to those in good-prognosis subclasses (ie, luminal A) via gene
expression profiling.[3,4] Interestingly, classic prognostic profiles applied to a set of basal-like
breast cancers (ie, 70-gene profile, recurrence score, and activated wound response signature)
uniformly gave poor-prognosis signatures despite significant variations in methodology and
little overlap in individual genes.[35]
Population-based studies have also demonstrated reduced breast cancer–specific survival
among patients with triple-negative disease as compared with luminal phenotypes.[27,28] A
recently reported Canadian series evaluating prognosis in over 1,500 women illustrated an
increased likelihood of distant recurrence (hazard ratio [HR] = 2.6, P < .0001) and death (HR
= 3.2, P < .0001) among women with triple-negative breast cancer compared to non–triple-
negative disease. Interestingly, the pattern of recurrence over a 5-year follow-up period was
substantially different among groups. Women with triple-negative breast cancer were much
more likely to develop a recurrence during the first 3 years following therapy with rapid
declines thereafter. Patients with non–triple-negative disease demonstrated more consistent
rates of recurrence over the follow-up period.[28]
Patterns of Recurrence
In addition to a distinct pattern of timing of recurrence, we are increasingly recognizing unique
patterns of relapse site among triple-negative breast cancer patients. Studies have consistently
shown that more aggressive visceral and soft-tissue relapse are more common and bone relapse
less common among those diagnosed with triple-negative vs ER-positive disease.[6,36]
Among 344 patients with lymph node–negative breast tumors treated solely with local therapy,
the intrinsic gene list was applied to classify molecular subtypes (ie, luminal, basal, HER2-
positive, etc), such that site-specific patterns of relapse could be determined. Bone relapse was
more likely to occur in luminal subtypes (especially luminal A, P = .056) but less likely in the
basal-like phenotypes (P = .0001). Lung metastasis was more frequently observed in the basal-
like subtype (P = .01) and less likely among luminal subtypes (P = .019). Finally, of the 14
cases of brain metastasis observed in this series, 8 were basal-like in origin (P = .035) compared
to only 2 of luminal origin (P = .0031), indicating a predilection for brain metastasis among
patients diagnosed with triple-negative disease.[36]
Brain Metastasis
An estimated 15% of all patients diagnosed with breast cancer will develop brain metastasis.
This figure, however, is likely an underestimate, as autopsy studies report a 30% rate of
subclinical disease. Despite currently available therapies including corticosteroids, whole-
brain radio-therapy, surgical resection, stereotactic radiosurgery, and supportive care, survival
following a diagnosis of brain metastasis remains quite poor, with a median survival of only
6 months and 1-year survival approximating 20%.[37,38] The increased incidence of brain
metastasis among patients with HER2-positive metastatic breast cancer has been documented
for several years, and targeted therapeutics—namely lapatinib (Tykerb)—have shown promise
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in the treatment of HER2-positive trastuzumab (Herceptin)-refractory, progressive brain
metastasis.[39,40]
More recent studies highlight the frequency and aggressiveness of intracranial metastasis in
triple-negative breast cancer, although similar systemic strategies are not yet available. In a
series of over 3,000 patients with brain metastasis arising from breast cancer treated from 1989
to 2006, multivariate analysis indicated that triple-negative status was the greatest risk factor
for the development of cerebral metastasis (odds ratio [OR] = 4.16; P < .001), above that of
HER2-positive status (OR = 3.43; P = .005). The median interval between primary diagnosis
and cerebral relapse was shorter among patients with triple-negative breast cancer than non–
triple-negative (22 vs 51 months, OR = 2.7; P < .0001), with a trend toward worse survival
after the diagnosis of brain metastasis (4 vs 8 months; P = NS) [5].
Another series of 222 patients with brain metastasis treated between 2003 and 2006 also found
inferior median survival for patients with triple-negative (3.7 months) vs HER2-positive (9
months) and ER/PR/HER2–positive (15 months) disease (P = .015).[41] Significant efforts are
focusing on the prediction of patients at highest risk for subsequent breast cancer–related brain
relapse, including both clinical nomograms and gene expression strategies.[42-44] The
majority of these efforts, however, have been directed at patients with HER2-positive disease.
The above studies provide ample evidence that predictive, preventive, and therapeutic
strategies in the setting of triple-negative intracranial relapse remain a challenge.
Therapeutic Strategies
Although triple-negative breast cancer is associated with a generally poor breast cancer–
specific outcome, it is not resistant to chemotherapy (Table 1). In the adjuvant setting,
retrospective review of a subset of patients treated on Cancer and Leukemia Group B (CALGB)
9344 suggested that the benefit of a taxane added to an anthracycline was primarily among
patients whose disease overexpressed HER2 or were double-negative (ER/HER2), most of
which are likely to be basal-like.[45]
Anthracycline/Taxane–Based Chemotherapy
Two neoadjuvant studies shed light upon the relationship between chemosensitivity and
outcome. Both revealed proportionally higher sensitivity to anthracycline- or anthracycline/
taxane–based chemotherapy for basal-like/ER-negative breast cancers compared to luminal/
ER-positive subtypes. One study compared clinical response among over 100 patients (32%
basal-like [ER-negative, HER2-negative], 10% HER2-positive/ER-negative, 58% luminal
[ER-positive]) treated with neoadjuvant AC (doxorubicin [Adriamycin]/cyclophosphamide)
chemotherapy and found the highest response rates among those classified as basal-like (85%)
and HER2-positive (70%), compared with luminal (47%; P < .0001). Despite initial
chemosensitivity, disease-free survival (P = .04) and overall survival (P = .02) remained
poorest among those with basal-like and HER2-positive tumors compared to luminal tumors.
[46]
A second study evaluated over 1,000 patients (23% triple-negative) treated with a variety of
anthracycline/taxane–based neoadjuvant strategies. Consistent with previous results, a higher
pathologic complete response was observed among patients with triple-negative disease
compared to ER-positive breast tumors (22% vs 11%, HR = 1.53, P = .34). In multivariate
analysis, triple-negative status was associated with decreased 3-year progression-free and
overall survival compared to non–triple-negative disease (63% vs 76%, HR = 1.86, P < .0001;
and 74% vs 89%, HR = 2.53, P < .000; respectively).[6]
ANDERS and CAREY Page 5













In both series, patients with a pathologic complete response had excellent outcomes regardless
of subtype. Patients with residual disease following neoadjuvant therapy were at highest risk
for recurrence. Thus, the poorer outcome among triple-negative patients was attributed to a
higher rate of recurrence among patients with residual disease. These studies of chemotherapy
response and patterns of recurrence highlight the value of neoadjuvant studies. They also reveal
that while there are patients with triple-negative disease who are well-treated with conventional
cytotoxic therapies, this subtype in particular requires more effective upfront therapies capable
of eradicating disease.
Traditionally, chemotherapy has been the mainstay of systemic treatment for triple-negative
breast cancer, since currently available targeted agents, including endocrine therapy and HER2-
directed therapies, are ineffective. As previously mentioned, triple-negative breast cancer is
highly responsive to primary anthracycline and anthracycline/taxane chemotherapy; however,
a high risk of relapse remains if tumor is not eradicated.[6,46,47] Preclinical and clinical studies
indicate that tumors with BRCA1 dysfunction harboring deficient double-stranded DNA break
repair mechanisms are sensitive to agents that cause DNA damage, such as platinum agents
(cisplatin and carboplatin).[48,49] The association between triple-negative breast cancer and
BRCA1 mutation status has led to several (neo)adjuvant and meta-static studies illustrating
activity of platinum-based regimens in the treatment of triple-negative breast cancer, although
how this activity compares with that of other cytotoxics remains unclear.[50-54]
Targeted Strategies
More recently, scientific efforts aimed at dissecting the biology of triple-negative breast cancer
have revealed several promising targeted strategies including EGFR-targeted agents,
antiangiogenic agents, and PARP inhibitors.
• EGFR Inhibitors—As mentioned previously, EGFR expression is seen in approximately
60% of triple-negative breast tumors, thus providing a rational, targeted treatment approach.
[10] Cetuximab (Erbitux) a chimeric monoclonal antibody targeting EGFR, elicits little
response to single-agent therapy in the setting of advanced triple-negative breast cancer.[50]
However, a phase II trial evaluating the combination of cetuximab and carboplatin (area under
the concentration-time curve [AUC]2, weekly for 3 of 4 weeks) reported a response rate of
18% and overall clinical benefit rate of 27% among 102 patients with advanced pretreated
triple-negative breast cancer. Time to progression was 2 months, and overall survival was 12
months, which reflects the aggressive nature of this disease.[55]
A second study evaluating the combination of irinotecan and carboplatin with or without
cetuximab reported response rates of 49% and 30%, respectively, among 72 patients with
pretreated triple-negative breast cancer. The incidence of toxicity, including grade 3/4 fatigue,
diarrhea, vomiting, neutropenia, and thrombocytopenia, was higher among patients who
received cetuximab.[52]
• PARP Inhibitors—PARP1, a gene that encodes a chromatin-associated enzyme that
modifies various nuclear proteins, is involved in the molecular events leading to cell recovery
from DNA damage. When PARP1 is inhibited, double-strand DNA breaks accumulate that
under normal conditions would be repaired via homologous recombination. Both BRCA1 and
BRCA2 are required for the homologous recombination pathway to function properly.
Therefore, cells deficient in either BRCA1 or BRCA2 are exquisitely sensitive to PARP1
inhibition, resulting in cell death/apoptosis.[56,57] Inhibition of the PARP pathway has
become an attractive research question for patients with BRCA-associated malignancies.
Several PARP1 inhibitors (ie, AZD2281, BSI-201) are currently in clinical development and
hold promise in this unique setting.[1,58,59]
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• Antiangiogenic Agents—The antiangiogenic agent bevacizumab (Avastin), a
monoclonal antibody targeting all forms of vascular endothelial growth factor (VEGF)-A, is
active in a variety of solid tumors including breast cancer. The landmark study E2100 illustrated
improvement in progression-free survival (11.8 vs 5.9 months, HR = 0.60, P < .001) when
adding bevacizumab to paclitaxel chemotherapy compared with single-agent paclitaxel alone
in first-line treatment of metastatic disease. Subset analyses indicated that the treatment effect
persisted among ER/PR–negative patients (HR = 0.53, 95% confidence interval = 0.40–0.70)
in this largely (> 90%) HER2-negative patient population.[60] Additionally, small-molecule
inhibitors of the VEGF pathway appear to have activity in the subset of pretreated triple-
negative breast cancer; definitive studies are underway.[61,62]
Reference Guide










Brand names are listed in parentheses only if a drug is not available generically and is
marketed as no more than two trademarked or registered products. More familiar alternative
generic designations may also be included parenthetically.
Several contemporary studies are examining antiangiogenic strategies alone or in tandem with
other investigational approaches in triple-negative breast cancer. CALGB 40603, for example,
is a neoadjuvant study examining the benefit of carboplatin added to paclitaxel and the benefit
of bevacizumab added to primary chemotherapy. Echoing the oft-noted need for better tissue
correlates in targeted therapy trials, this is a clinical trial with correlative science studies
embedded; pretherapy research biopsies are mandatory. This trial, which is expected to open
to accrual in the fall of 2008, will not only help answer two specific clinical questions in triple-
negative breast cancer—the role of platinum agents and the role of antiangiogenics—but in
addition, it will provide crucial data regarding response and resistance patterns within this
subtype.
Conclusions
In summary, triple-negative breast cancer largely represents a subtype of breast tumors with
unique molecular and clinical characteristics, distinctive risk factors and patterns of recurrence,
association with BRCA1 mutation status, inferior prognosis, and expanding therapeutic
options. Multiple excellent approaches to improved care of triple-negative breast cancer,
including DNA-damaging agents such as platinums, targeted agents against EGFR and VEGF,
and PARP inhibitors are under investigation. Current research strategies are aimed at better
understanding both the risk factors and the biology underlying triple-negative breast cancer,
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with the goal of developing preventive measures and improving treatment strategies for this
challenging subtype of breast cancer.
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Table 1
Classic Molecular Features of Luminal vs Basal Epithelial Cells
Luminal Epithelial Cell Markers Basal Epithelial Cell Markers
Higher Expression Higher Expression
CK7, CK8, CK18, CK19 CK5, CK14, CK17
MUC1 Smooth muscle markers
Alpha-6 integrin Calponin, caldesmon
BCL2 p63, beta-4 integrin
ER Laminin, maspin
PR CD10, P-cadherin, caveolin-1
GATA3 NGFR
Epithelial cell adhesion molecules HER1/EGFR
Lower Expression Lower Expression
Basal CK (CK5, CK14, CK17) ER, PR, HER2
HER2 Desmin
CK = cytokeratins; EGFR = epidermal growth factor receptor; ER = estrogen receptor; NGFR = nerve growth factor receptor; PR = progesterone
receptor.
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Table 2




Platinum agents Active, comparison to other cytotoxics unclear[51]
Bevacizumab Suggested in subset analyses of unselected phase III trial, E2100[60]
Sunitinib Suggested by subset analyses of unselected phase II trial[62]
EGFR inhibition Preclinical data, modest activity with chemotherapy in phase II studies[52,55]
PARP inhibition Preclinical data, in investigation
EGFR = epidermal growth factor receptor; PARP = poly ADP-ribose polymerase.
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